Cassava Sciences, Inc. (SAVA)

23.95 +0.42 (+1.78%) At close: 04:00PM EDT

Cassava Sciences, Inc.

6801 N. Capital of Texas Highway, Building 1
Suite 300
Austin, TX 78731
United States
512 501 2444
https://www.cassavasciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 26

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Remi Barbier	Founder, Chairman, Pres & CEO	1.74M	114.86k	1960
Mr. Eric J. Schoen	Chief Financial Officer	776.93k	N/A	1968
Dr. James W. Kupiec M.D.	Chief Medical Officer	476.57k	N/A	N/A
Dr. George Thornton	Sr. VP of Technology	N/A	N/A	N/A
Mr. R. Christopher Cook	Sr. VP & Gen. Counsel	N/A	N/A	N/A
Mr. Michael Zamloot	Sr. VP of Technical Operations	N/A	N/A	N/A
Dr. Michael Marsman Pharm.D.	Sr. VP of Regulatory Affairs	N/A	N/A	N/A
Dr. Lindsay H. Burns Ph.D.	Sr. VP of Neuroscience	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Corporate Governance

Cassava Sciences, Inc.’s ISS Governance QualityScore as of March 1, 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.